Kosj Yamoah, MD, PhD

Dr. Yamoah is a board-certified radiation oncologist and physician scientist with expertise in cancer health disparities spanning clinical care, and translational research. He directs a global laboratory that focuses on the identification of clinically relevant environmental and biological contributions to aggressive disease and poor survival in men of African origin with prostate cancer and has established international research partnerships with academic centers in Africa to study prostate cancer.

Associations

• Radiation Oncology
• Cancer Epidemiology
• Cancer Epidemiology Program

Education & Training

Graduate:

• Mount Sinai Graduate School of Biological Sciences & Memorial Sloan-Kettering Cancer Center, PhD - Oncological Science

Fellowship:

• University of Pennsylvania - Molecular Epidemiology, Department of Epidemiology and Population Sciences

Residency:

• Atlantic Health, New Jersey - Internship
• Korle Bu Teaching Hospital - Radiation Oncology Research
• St. Jude Children's Research Hospital - Pediatric Radiation Oncology
• Washington University - Gynecologic Brachytherapy
• Thomas Jefferson University Hospital - Radiation Oncology

Medical School:

• Mount Sinai School of Medicine - MD

Dr. Yamoah’s research utilizes a multidisciplinary approach that combines methods from epidemiology, biostatistics, bioinformatics, pathology, molecular biology, and genomic studies.  His laboratory research focuses on developing novel approaches to better predict aggressive disease and appropriately treat men of African descent with prostate cancer. Recently, work done in his lab show that prostate tumors from African-American men have a immunosuppressive tumor immune microenvironment characterized by low DNA damage repair and high IFN-response pathways.  This body of work will promote a genomic-adaptive approach to treating prostate cancer in African-American men – a step towards personalized medicine.

Clinical Trial 19291
The Utility of PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men with High GC Decipher® Test Scores: A Sub-aim of the VANDAAM Study (MCC #18523)
Condition: Genitourinary
Status: Open

Clinical Trial 50428
Metabolite Consumption in Patient-Derived Explants to Predict Therapeutic Response in Aggressive and Oligometastatic Prostate Cancer in African American Men
Condition: Genitourinary
Status: Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

• Wadhwa A, Roscoe C, Duran EA, Kwan L, Haroldsen CL, Shelton JB, Cullen J, Knudsen BS, Rettig MB, Pyarajan S, Nickols NG, Maxwell KN, Yamoah K, Rose BS, Rebbeck TR, Iyer HS, Garraway IP. Neighborhood Deprivation, Race and Ethnicity, and Prostate Cancer Outcomes Across California Health Care Systems. JAMA Netw Open. 2024 Mar.7(3):e242852. Pubmedid: 38502125. Pmcid: PMC10951732.
• Esen T, Esen B, Yamaoh K, Selek U, Tilki D. De-Escalation of Therapy for Prostate Cancer. Am Soc Clin Oncol Educ Book. 2024 Jan.44(2):e430466. Pubmedid: 38206291.
• Deville C, Kamran SC, Morgan SC, Yamoah K, Vapiwala N. Radiation Therapy Summary of the AUA/ASTRO Guideline on Clinically Localized Prostate Cancer. Pract Radiat Oncol. 2024 Jan.14(1):47-56. Pubmedid: 38182303.
• Lee KM, Bryant AK, Lynch JA, Robison B, Alba PR, Agiri FY, Pridgen KM, DuVall SL, Yamoah K, Garraway IP, Rose BS. Association between prediagnostic prostate-specific antigen and prostate cancer probability in Black and non-Hispanic White men. Cancer. 2024 Jan.130(2):224-231. Pubmedid: 37927109.
• Lee KM, Nelson T, Bryant A, Teerlink C, Gulati R, Pagadala M, Tcheandjieu C, Pridgen KM, DuVall SL, Yamoah K, Vassy JL, Seibert TM, Hauger R, Rose BS, Lynch JA. Genetic risk and likelihood of prostate cancer detection on first biopsy by ancestry. J Natl Cancer Inst. 2024 Jan. Pubmedid: 38212986.
• Cho HL, Perni S, D'Amico AV, Yamoah K, Dee EC. The imperative for clinical trial diversity: Perspectives in the context of prostate-specific membrane antigen-targeted imaging. Prostate Cancer P D. 2023 Sep.26(3):511-515. Pubmedid: 36872319.
• Weygand J, Armstrong T, Bryant JM, Andreozzi JM, Oraiqat IM, Nichols S, Liveringhouse CL, Latifi K, Yamoah K, Costello JR, Frakes JM, Moros EG, El Naqa IM, Naghavi AO, Rosenberg SA, Redler G. Accurate, repeatable, and geometrically precise diffusion-weighted imaging on a 0.35 T magnetic resonance imaging-guided linear accelerator. Phys Imaging Radiat Oncol. 2023 Oct.28:100505. Pubmedid: 38045642. Pmcid: PMC10692914.
• Kutuva AR, Caudell JJ, Yamoah K, Enderling H, Zahid MU. Mathematical modeling of radiotherapy: impact of model selection on estimating minimum radiation dose for tumor control. Front Oncol. 2023 Oct.13:1130966. Pubmedid: 37901317. Pmcid: PMC10600389.
• Valle LF, Nickols NG, Yamoah K, Garraway IP, Maxwell KN, Lynch JA. In Reply to "Pathogenic/Likely Pathogenic Somatic CDK12 Mutations in Black Men With Prostate Cancer". Oncologist. 2023 Nov.28(11):e1129-e1130. Pubmedid: 37706534. Pmcid: PMC10628590.
• Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jereczek-Fossa BA, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khauli RB, Klotz L, Kramer G, Leibowitz R, Logothetis C, Mahal B, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro CJ, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale CL, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Zilli T, Omlin A. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Eur J Cancer. 2023 May.185:1 ...
• Liveringhouse C, Netzley A, Bryant JM, Linkowski LC, Weygand J, Sandoval ML, Dohm A, Dookhoo M, Kelley S, Rosenberg SA, Latifi K, Torres-Roca JF, Johnstone PAS, Yamoah K, Grass GD. Trimodal Therapy Using an MR-guided Radiation Therapy Partial Bladder Tumor Boost in Muscle Invasive Bladder Cancer. Adv Radiat Oncol. 2023 May.8(6):101268. Pubmedid: 38047218. Pmcid: PMC10692296.
• Baliga S, Yildiz VO, Bazan J, Palmer JD, Jhawar SR, Konieczkowski DJ, Grecula J, Blakaj DM, Mitchell D, Henson C, Hu K, Yamoah K, Gamez ME. Disparities in Survival Outcomes among Racial/Ethnic Minorities with Head and Neck Squamous Cell Cancer in the United States. Cancers (Basel). 2023 Mar.15(6). Pubmedid: 36980667. Pmcid: PMC10046381.
• Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ngozi Ekeke O, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Alicja Jereczek-Fossa B, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khauli RB, Klotz L, Kramer G, Leibowitz R, Logothetis CJ, Mahal BA, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Pablo Sade J, Sartor OA, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale CL, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Zilli T, Omlin A. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Adv ...
• Bukavina L, Luckenbaugh AN, Hofman MS, Hope T, Kamran SC, Murphy DG, Yamoah K, Ost P. Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer. Eur Urol. 2023 Jun.83(6):521-533. Pubmedid: 36404204.
• Li X, Roy S, Damonte J, Park HY, Hoogland AI, Jamison K, Komrokji KR, Yeo CD, Kim Y, Dhillon J, Gudenkauf LM, Oswald LB, Jim HSL, Yamoah K, Pow-Sang JM, Kanetsky PA, Gwede CK, Park JY, Gonzalez BD. Recruiting African American Prostate Cancer Survivors for a Population-based Biobank Study. Cancer Epidemiol Biomarkers Prev. 2023 Jun.32(6):768-775. Pubmedid: 36958853. Pmcid: PMC10308568.
• Swami N, Baez YA, Franco I, Nguyen T, Meiyappan K, Ton M, Jain B, Seldon C, Ng K, Duma N, Alshalalfa M, Yamoah K, Nguyen PL, Mahal BA, Dee EC. Localized prostate cancer disparities in risk group at presentation and access to treatment for Hispanic men. Prostate Cancer P D. 2023 Jun.26(2):309-316. Pubmedid: 35306541.
• Valle LF, Nickols NG, Hausler R, Alba PR, Anglin-Foote T, Perez C, Yamoah K, Rose BS, Kelley MJ, DuVall SL, Garraway IP, Maxwell KN, Lynch JA. Actionable Genomic Alterations in Prostate Cancer Among Black and White United States Veterans. Oncologist. 2023 Jun.28(6):e473-e477. Pubmedid: 37084789. Pmcid: PMC10243786.
• Chen F, Madduri RK, Rodriguez AA, Darst BF, Chou A, Sheng X, Wang A, Shen J, Saunders EJ, Rhie SK, Bensen JT, Ingles SA, Kittles RA, Strom SS, Rybicki BA, Nemesure B, Isaacs WB, Stanford JL, Zheng W, Sanderson M, John EM, Park JY, Xu J, Wang Y, Berndt SI, Huff CD, Yeboah ED, Tettey Y, Lachance J, Tang W, Rentsch CT, Cho K, Mcmahon BH, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Sellers TA, Yamoah K, Murphy AB, Crawford DC, Patel AV, Bush WS, Aldrich MC, Cussenot O, Petrovics G, Cullen J, Neslund-Dudas CM, Stern MC, Kote-Jarai Z, Govindasami K, Cook MB, Chokkalingam AP, Hsing AW, Goodman PJ, Hoffmann TJ, Drake BF, Hu JJ, Keaton JM, Hellwege JN, Clark PE, Jalloh M, Gueye SM, Niang L, Ogunbiyi O, Idowu MO, Popoola O, Adebiyi AO, Aisuodionoe-Shadrach OI, Ajibola HO, Jamda MA, Oluwole OP, Nwegbu M, Adusei B, Mante S, Darkwa-Abrahams A, Mensah JE, Diop H, Van Den Eeden SK, Blanchet P, Fowke JH, Casey G, Hennis AJ, Lubwama A, Thompson IM, Leach R, Easton DF, Preuss MH, Loos RJ, Gundell SM, Wan P, Mohler JL, Fontham ET, Smith GJ, Taylor JA, Srivastava S, Eeles RA, Carpten JD, Kibel AS, Multigner L, Parent MÉ, Menegaux F, Cancel-Tassin G, Klein EA, Andrews C, Rebbeck TR, Brureau L, Ambs S, Edwards TL, Watya S, Chanock SJ, Witte JS, Blot WJ, Michael Gaziano J, Justice AC, Conti DV, Haiman CA. Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry. Eur Urol. 2023 Jul. ...
• Buro AW, Carson TL, Small BJ, Fan W, Oswald LB, Jim HSL, Salas E, Zambrano K, Bryant C, Yamoah K, Gwede CK, Park JY, Gonzalez BD. Sociocultural factors associated with physical activity in Black prostate cancer survivors. Support Care Cancer. 2023 Jul.31(8):482. Pubmedid: 37479918. Pmcid: PMC10388711.
• Fink AKC, DeRenzis AC, Awasthi S, Jahan N, Johnstone PAS, Pow-Sang J, Torres-Roca J, Grass D, Fernandez D, Naghavi A, Tan S, Manley B, Li R, Poch M, Yu A, Little N, Bass E, Ercole CE, Katsoulakis E, Burri R, Smith R, Stanley NB, Vadaparampil ST, Yamoah K. Identifying and overcoming barriers to participation of minority populations in clinical trials: Lessons learned from the VanDAAM study. Cancer Med. 2023 Jan.12(2):1869-1877. Pubmedid: 35796421. Pmcid: PMC9883445.
• Dee EC, Taunk NK, Chino FL, Deville C, McClelland S, Muralidhar V, McBride SN, Gillespie EF, Yamoah K, Nguyen PL, Mahal BA, Winkfield KM, Vapiwala N, Santos PMG. Shorter Radiation Regimens and Treatment Noncompletion Among Patients With Breast and Prostate Cancer in the United States: An Analysis of Racial Disparities in Access and Quality. JCO Oncol Pract. 2023 Feb.19(2):e197-e212. Pubmedid: 36399692. Pmcid: PMC9970278.
• Wang A, Shen J, Rodriguez AA, Saunders EJ, Chen F, Janivara R, Darst BF, Sheng X, Xu Y, Chou AJ, Benlloch S, Dadaev T, Brook MN, Plym A, Sahimi A, Hoffman TJ, Takahashi A, Matsuda K, Momozawa Y, Fujita M, Laisk T, Figuerêdo J, Muir K, Ito S, Liu X, Uchio Y, Kubo M, Kamatani Y, Lophatananon A, Wan P, Andrews C, Lori A, Choudhury PP, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Giles GG, Southey MC, MacInnis RJ, Cybulski C, Wokolorczyk D, Lubinski J, Rentsch CT, Cho K, Mcmahon BH, Neal DE, Donovan JL, Hamdy FC, Martin RM, Nordestgaard BG, Nielsen SF, Weischer M, Bojesen SE, Røder A, Stroomberg HV, Batra J, Chambers S, Horvath L, Clements JA, Tilly W, Risbridger GP, Gronberg H, Aly M, Szulkin R, Eklund M, Nordstrom T, Pashayan N, Dunning AM, Ghoussaini M, Travis RC, Key TJ, Riboli E, Park JY, Sellers TA, Lin HY, Albanes D, Weinstein S, Cook MB, Mucci LA, Giovannucci E, Lindstrom S, Kraft P, Hunter DJ, Penney KL, Turman C, Tangen CM, Goodman PJ, Thompson IM, Hamilton RJ, Fleshner NE, Finelli A, Parent MÉ, Stanford JL, Ostrander EA, Koutros S, Beane Freeman LE, Stampfer M, Wolk A, Håkansson N, Andriole GL, Hoover RN, Machiela MJ, Sørensen KD, Borre M, Blot WJ, Zheng W, Yeboah ED, Mensah JE, Lu YJ, Zhang HW, Feng N, Mao X, Wu Y, Zhao SC, Sun Z, Thibodeau SN, McDonnell SK, Schaid DJ, West CML, Barnett G, Maier C, Schnoeller T, Luedeke M, Kibel AS, Drake BF, Cussenot O, Cancel-Tassin G, Menegaux F, Truong T, Koudou YA, John EM, Grindedal EM, Maehle L, Khaw KT, Ingles SA, Ster ...
• Patel TA, Jain B, Vapiwala N, Chino F, Tringale KR, Mahal BA, Yamoah K, McBride SN, Lam MB, Hubbard A, Nguyen PL, Dee EC. Trends in Utilization and Medicare Spending on Short-Course Radiation Therapy for Breast and Prostate Cancer: An Episode-Based Analysis From 2015 to 2019. Int J Radiat Oncol Biol Phys. 2023 Dec. Pubmedid: 38072324.
• Ottman R, Ganapathy K, Lin HY, Osterman CD, Dutil J, Matta J, Ruiz-Deya G, Wang L, Yamoah K, Berglund A, Chakrabarti R, Park JY. Differential Expression of miRNAs Contributes to Tumor Aggressiveness and Racial Disparity in African American Men with Prostate Cancer. Cancers (Basel). 2023 Apr.15(8). Pubmedid: 37190259. Pmcid: PMC10136561.
• Jain B, Yamoah K, Lathan CS, Muralidhar V, Mahal BA, Nguyen PL, Dee EC. Racial disparities in treatment delay among younger men with prostate cancer. Prostate Cancer P D. 2022 Sep.25(3):590-592. Pubmedid: 35190652.
• Awasthi S, Mahal BA, Park JY, Creed JH, Williams VL, Elkenawi A, Meadows SO, Pow-Sang JM, Lu-Yao G, Kelly WK, Lang DY, Zgibor J, Rebbeck TR, Yamoah K. Substantial Gleason reclassification in Black men with national comprehensive cancer network low-risk prostate cancer - A propensity score analysis. Prostate Cancer P D. 2022 Sep.25(3):547-552. Pubmedid: 35194179. Pmcid: PMC9838824.
• Darst BF, Hughley R, Pfennig A, Hazra U, Fan C, Wan P, Sheng X, Xia L, Andrews C, Chen F, Berndt SI, Kote-Jarai Z, Govindasami K, Bensen JT, Ingles SA, Rybicki BA, Nemesure B, John EM, Fowke JH, Huff CD, Strom SS, Isaacs WB, Park JY, Zheng W, Ostrander EA, Walsh PC, Carpten J, Sellers TA, Yamoah K, Murphy AB, Sanderson M, Crawford DC, Gapstur SM, Bush WS, Aldrich MC, Cussenot O, Petrovics G, Cullen J, Neslund-Dudas C, Kittles RA, Xu J, Stern MC, Chokkalingam AP, Multigner L, Parent ME, Menegaux F, Cancel-Tassin G, Kibel AS, Klein EA, Goodman PJ, Stanford JL, Drake BF, Hu JJ, Clark PE, Blanchet P, Casey G, Hennis AJM, Lubwama A, Thompson IM, Leach RJ, Gundell SM, Pooler L, Mohler JL, Fontham ETH, Smith GJ, Taylor JA, Brureau L, Blot WJ, Biritwum R, Tay E, Truelove A, Niwa S, Tettey Y, Varma R, McKean-Cowdin R, Torres M, Jalloh M, Magueye Gueye S, Niang L, Ogunbiyi O, Oladimeji Idowu M, Popoola O, Adebiyi AO, Aisuodionoe-Shadrach OI, Nwegbu M, Adusei B, Mante S, Darkwa-Abrahams A, Yeboah ED, Mensah JE, Anthony Adjei A, Diop H, Cook MB, Chanock SJ, Watya S, Eeles RA, Chiang CWK, Lachance J, Rebbeck TR, Conti DV, Haiman CA. A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry. Eur Urol. 2022 May.81(5):458-462. Pubmedid: 35031163. Pmcid: PMC9018520.
• Awasthi S, Yamoah K. EDITORIAL COMMENT. Urology. 2022 May.163:89. Pubmedid: 35636865.
• Rebbeck TR, Mahal B, Maxwell KN, Garraway IP, Yamoah K. The distinct impacts of race and genetic ancestry on health. Nat Med. 2022 May.28(5):890-893. Pubmedid: 35534567.
• Kensler KH, Awasthi S, Alshalalfa M, Trock BJ, Freedland SJ, Freeman MR, You S, Mahal BA, Den RB, Dicker AP, Karnes RJ, Klein EA, Lal P, Liu Y, Davicioni E, Rayford W, Yamoah K, Rebbeck TR. Variation in Molecularly Defined Prostate Tumor Subtypes by Self-identified Race. Eur Urol Open Sci. 2022 Jun.40:19-26. Pubmedid: 35638091. Pmcid: PMC9142751.
• Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ekeke Onyeanunam N, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Pablo Sade J, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg CN, Suzuki H, Sweeney C, Sydes M, Taplin ME, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Gillessen S, Omlin A. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022 Jul.82(1):6-11. Pubmedid: 35393158. Pmcid: PMC8849852.
• Gillessen S, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke CS, Clarke N, Davis ID, de Bono JS, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt DE, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022 Jul.82(1):115-141. Pubmedid: 35450732.
• Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ekeke ON, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg CN, Suzuki H, Sweeney C, Sydes M, Taplin ME, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Gillessen S, Omlin A. Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11]. Eur Urol. 2022 Jul.82(1):e18-e19. Pubmedid: 35440417. Pmcid: PMC9012951.
• Yamoah K, Lee KM, Awasthi S, Alba PR, Perez C, Anglin-Foote TR, Robison B, Gao A, DuVall SL, Katsoulakis E, Wong YN, Markt SC, Rose BS, Burri R, Wang C, Aboiralor O, Fink AK, Nickols NG, Lynch JA, Garraway IP. Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care System. JAMA Netw Open. 2022 Jan.5(1):e2144027. Pubmedid: 35040965. Pmcid: PMC8767437.
• Mahal BA, Gerke T, Awasthi S, Soule HR, Simons JW, Miyahira A, Halabi S, George D, Platz EA, Mucci L, Yamoah K. Prostate Cancer Racial Disparities: A Systematic Review by the Prostate Cancer Foundation Panel. Eur Urol Oncol. 2022 Feb.5(1):18-29. Pubmedid: 34446369.
• Johnstone PAS, Spiess PE, Sedor G, Grass GD, Yamoah K, Scott JG, Torres-Roca JF. Changing Radiotherapy Paradigms in Penile Cancer. Eur Urol Open Sci. 2022 Feb.36:47-48. Pubmedid: 35028598. Pmcid: PMC8739469.
• Awasthi S, Grass GD, Torres-Roca J, Johnstone PAS, Pow-Sang J, Dhillon J, Park J, Rounbehler RJ, Davicioni E, Hakansson A, Liu Y, Fink AK, DeRenzis A, Creed JH, Poch M, Li R, Manley B, Fernandez D, Naghavi A, Gage K, Lu-Yao G, Katsoulakis E, Burri RJ, Leone A, Ercole CE, Palmer JD, Vapiwala N, Deville C, Rebbeck TR, Dicker AP, Kelly W, Yamoah K. Genomic Testing in Localized Prostate Cancer Can Identify Subsets of African Americans With Aggressive Disease. J Natl Cancer Inst. 2022 Dec.114(12):1656-1664. Pubmedid: 36053178. Pmcid: PMC9745424.
• Yamoah K, Awasthi S, Mahal BA, Zhao SG, Grass GD, Berglund A, Abraham-Miranda J, Gerke T, Rounbehler RJ, Davicioni E, Liu Y, Park J, Cleveland JL, Pow-Sang JM, Fernandez D, Torres-Roca J, Karnes RJ, Schaeffer E, Freedland SJ, Spratt DE, Den RB, Rebbeck TR, Feng F. Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer. Eur Urol. 2022 Apr.81(4):325-330. Pubmedid: 33303244.
• Qiao EM, Lynch JA, Lee KM, Kotha NV, Nalawade V, Voora RS, Qian AS, Nelson TJ, Yamoah K, Garraway IP, Stewart TF, Parsons JK, Rose BS. Evaluating Prostate-Specific Antigen Screening for Young African American Men With Cancer. J Natl Cancer Inst. 2022 Apr.114(4):592-599. Pubmedid: 34893859. Pmcid: PMC9002290.
• Klebaner D, Travis Courtney P, Garraway IP, Einck J, Kumar A, Elena Martinez M, McKay R, Murphy JD, Parada H, Sandhu A, Stewart T, Yamoah K, Rose BS. Association of Health-Care System With Prostate Cancer-Specific Mortality in African American and Non-Hispanic White Men. J Natl Cancer Inst. 2021 Oct.113(10):1343-1351. Pubmedid: 33892497. Pmcid: PMC8486332.
• El-Kenawi A, Dominguez-Viqueira W, Liu M, Awasthi S, Abraham-Miranda J, Keske A, Steiner KK, Noel L, Serna AN, Dhillon J, Gillies RJ, Yu X, Koomen JM, Yamoah K, Gatenby RA, Ruffell B. Macrophage-Derived Cholesterol Contributes to Therapeutic Resistance in Prostate Cancer. Cancer Res. 2021 Nov.81(21):5477-5490. Pubmedid: 34301759. Pmcid: PMC8563406.
• Peacock J, Sikariam D, Maun-Garcia L, Javedan K, Yamoah K, Parikh N. A Proof-of-Concept Study on the Use of Prostate Artery Embolization Before Definitive Radiation Therapy in Prostate Cancer. Adv Radiat Oncol. 2021 May.6(3):100619. Pubmedid: 33748542. Pmcid: PMC7966837.
• Leo P, Janowczyk A, Elliott R, Janaki N, Bera K, Shiradkar R, Farré X, Fu P, El-Fahmawi A, Shahait M, Kim J, Lee D, Yamoah K, Rebbeck TR, Khani F, Robinson BD, Eklund L, Jambor I, Merisaari H, Ettala O, Taimen P, Aronen HJ, Boström PJ, Tewari A, Magi-Galluzzi C, Klein E, Purysko A, Nc Shih N, Feldman M, Gupta S, Lal P, Madabhushi A. Computer extracted gland features from H&E predicts prostate cancer recurrence comparably to a genomic companion diagnostic test: a large multi-site study. NPJ Precis Oncol. 2021 May.5(1):35. Pubmedid: 33941830. Pmcid: PMC8093226.
• Yuan Z, Fernandez D, Dhillon J, Abraham-Miranda J, Awasthi S, Kim Y, Zhang J, Jain R, Serna A, Pow-Sang JM, Poch M, Li R, Manley B, Fink A, Naghavi A, Torres-Roca JF, Grass GD, Kim S, Latifi K, Hunt D, Johnstone PAS, Yamoah K. Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis. Prostate Cancer P D. 2021 Mar.24(1):140-149. Pubmedid: 32651467. Pmcid: PMC7882397.
• Ayettey Anie H, Yarney J, Sanuade O, Awasthi S, Ndanu TA, Parekh AD, Aidoo C, Dadzie MA, Vanderpuye V, Yamoah K. Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer in Sub-Saharan Africa: A Retrospective Analysis of Recurrence and Survival in Women Treated for Breast Cancer at the Korle Bu Teaching Hospital in Ghana. JCO Glob Oncol. 2021 Jun.7:965-975. Pubmedid: 34156868. Pmcid: PMC8457842.
• Rayford W, Beksac AT, Alger J, Alshalalfa M, Ahmed M, Khan I, Falagario UG, Liu Y, Davicioni E, Spratt DE, Schaeffer EM, Feng FY, Mahal B, Nguyen PL, Den RB, Greenberger MD, Bradley R, Watson JM, Beamer M, Stamatakis L, Carmen DJ, Awasthi S, Hwang J, Weil R, Merisaari H, Mohamed N, Deane LA, Chakravarty D, Yadav KK, Yamoah K, Nair SS, Tewari AK. Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences. Commun Biol. 2021 Jun.4(1):670. Pubmedid: 34083737. Pmcid: PMC8175556.
• Parikh N, Keshishian E, Manley B, Grass GD, Torres-Roca J, Boulware D, Feuerlein S, Pow-Sang JM, Bagla S, Yamoah K, Bhatia S. Effectiveness and Safety of Prostatic Artery Embolization for the Treatment of Lower Urinary Tract Symptoms from Benign Prostatic Hyperplasia in Men with Concurrent Localized Prostate Cancer. J Vasc Interv Radiol. 2021 Jul.32(7):1053-1061. Pubmedid: 33794373.
• Sandoval ML, Youssef I, Latifi K, Grass GD, Torres-Roca J, Rosenberg S, Yamoah K, Johnstone PA. Non-Adaptive MR-Guided Radiotherapy for Prostate SBRT: Less Time, Equal Results. J Clin Med. 2021 Jul.10(15). Pubmedid: 34362179. Pmcid: PMC8347281.
• Sandoval ML, Dohm A, Yamoah K. Management of early-stage metastatic prostate cancer: appraisal of locoregional treatments and radiation therapy, with or without immunomodulation. Endocr Relat Cancer. 2021 Jul.28(8):T109-T120. Pubmedid: 34061766.
• Leo P, Chandramouli S, Farré X, Elliott R, Janowczyk A, Bera K, Fu P, Janaki N, El-Fahmawi A, Shahait M, Kim J, Lee D, Yamoah K, Rebbeck TR, Khani F, Robinson BD, Shih NNC, Feldman M, Gupta S, McKenney J, Lal P, Madabhushi A. Computationally Derived Cribriform Area Index from Prostate Cancer Hematoxylin and Eosin Images Is Associated with Biochemical Recurrence Following Radical Prostatectomy and Is Most Prognostic in Gleason Grade Group 2. Eur Urol Focus. 2021 Jul.7(4):722-732. Pubmedid: 33941504. Pmcid: PMC8419103.
• Awasthi S, Berglund AE, Abraham-Miranda J, Rounbehler RJ, Kensler KH, Serna AN, Vidal AC, You S, Freeman MR, Davicioni E, Liu Y, Karnes JR, Klein EA, Den RB, Trock BJ, Campbell JD, Einstein DJ, Gupta R, Balk SP, Lal P, Park JY, Cleveland JL, Rebbeck TR, Freedland SJ, Yamoah K. Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer. Clin Cancer Res. 2021 Jan.27(1):320-329. Pubmedid: 33037017. Pmcid: PMC8042600.
• Yamoah K, Lal P, Awasthi S, Naghavi AO, Rounbehler RJ, Gerke T, Berglund AE, Pow-Sang JM, Schaeffer EM, Dhillon J, Park JY, Rebbeck TR. TMPRSS2-ERG fusion impacts anterior tumor location in men with prostate cancer. Prostate. 2021 Feb.81(2):109-117. Pubmedid: 33141952. Pmcid: PMC7810127.
• McKay RR, Sarkar RR, Kumar A, Einck JP, Garraway IP, Lynch JA, Mundt AJ, Murphy JD, Stewart TF, Yamoah K, Rose BS. Outcomes of Black men with prostate cancer treated with radiation therapy in the Veterans Health Administration. Cancer. 2021 Feb.127(3):403-411. Pubmedid: 33036065.
• Berglund A, Matta J, Encarnación-Medina J, Ortiz-Sanchéz C, Dutil J, Linares R, Marcial J, Abreu-Takemura C, Moreno N, Putney R, Chakrabarti R, Lin HY, Yamoah K, Osterman CD, Wang L, Dhillon J, Kim Y, Kim SJ, Ruiz-Deya G, Park JY. Dysregulation of DNA Methylation and Epigenetic Clocks in Prostate Cancer among Puerto Rican Men. Biomolecules. 2021 Dec.12(1). Pubmedid: 35053153. Pmcid: PMC8773891.
• Yamoah K, Asamoah FA, Abrahams AOD, Awasthi S, Mensah JE, Dhillon J, Mahal BA, Gueye SM, Jalloh M, Farahani SJ, Lal P, Rebbeck TR, Yarney J. Prostate tumors of native men from West Africa show biologically distinct pathways-A comparative genomic study. Prostate. 2021 Dec.81(16):1402-1410. Pubmedid: 34529278. Pmcid: PMC8563425.
• Abraham-Miranda J, Awasthi S, Yamoah K. Immunologic disparities in prostate cancer between American men of African and European descent. Crit Rev Oncol Hematol. 2021 Aug.164:103426. Pubmedid: 34273500.
• Lin HY, Huang PY, Cheng CH, Tung HY, Fang Z, Berglund AE, Chen A, French-Kwawu J, Harris D, Pow-Sang J, Yamoah K, Cleveland JL, Awasthi S, Rounbehler RJ, Gerke T, Dhillon J, Eeles R, Kote-Jarai Z, Muir K, Schleutker J, Pashayan N, Neal DE, Nielsen SF, Nordestgaard BG, Gronberg H, Wiklund F, Giles GG, Haiman CA, Travis RC, Stanford JL, Kibel AS, Cybulski C, Khaw KT, Maier C, Thibodeau SN, Teixeira MR, Cannon-Albright L, Brenner H, Kaneva R, Pandha H, Srinivasan S, Clements J, Batra J, Park JY. KLK3 SNP-SNP interactions for prediction of prostate cancer aggressiveness. Sci Rep. 2021 Apr.11(1):9264. Pubmedid: 33927218. Pmcid: PMC8084951.
• Liveringhouse C, Sim A, Yamoah K, Poch M, Wilder RB, Pow-Sang J, Johnstone PAS. Phase I dose escalation trial of stereotactic radiotherapy prior to robotic prostatectomy in high risk prostate cancer. Rep Pract Oncol Radiother. 2021 Apr.26(2):188-195. Pubmedid: 34211768. Pmcid: PMC8241300.
• Darst BF, Wan P, Sheng X, Bensen JT, Ingles SA, Rybicki BA, Nemesure B, John EM, Fowke JH, Stevens VL, Berndt SI, Huff CD, Strom SS, Park JY, Zheng W, Ostrander EA, Walsh PC, Srivastava S, Carpten J, Sellers TA, Yamoah K, Murphy AB, Sanderson M, Crawford DC, Gapstur SM, Bush WS, Aldrich MC, Cussenot O, Yeager M, Petrovics G, Cullen J, Neslund-Dudas C, Kittles RA, Xu J, Stern MC, Kote-Jarai Z, Govindasami K, Chokkalingam AP, Multigner L, Parent ME, Menegaux F, Cancel-Tassin G, Kibel AS, Klein EA, Goodman PJ, Drake BF, Hu JJ, Clark PE, Blanchet P, Casey G, Hennis AJM, Lubwama A, Thompson IM, Leach R, Gundell SM, Pooler L, Xia L, Mohler JL, Fontham ETH, Smith GJ, Taylor JA, Eeles RA, Brureau L, Chanock SJ, Watya S, Stanford JL, Mandal D, Isaacs WB, Cooney K, Blot WJ, Conti DV, Haiman CA. A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry. Eur Urol. 2020 Sep.78(3):316-320. Pubmedid: 32409115. Pmcid: PMC7805560.
• Howard LE, Zhang J, Fishbane N, Hoedt AM, Klaassen Z, Spratt DE, Vidal AC, Lin D, Hitchins MP, You S, Freeman MR, Yamoah K, Davicioni E, Freedland SJ. Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical prostatectomy in an equal access healthcare setting. Prostate Cancer P D. 2020 Sep.23(3):419-428. Pubmedid: 31844180.
• Mahal BA, Alshalalfa M, Kensler KH, Chowdhury-Paulino I, Kantoff P, Mucci LA, Schaeffer EM, Spratt D, Yamoah K, Nguyen PL, Rebbeck TR. Racial Differences in Genomic Profiling of Prostate Cancer. N Engl J Med. 2020 Sep.383(11):1083-1085. Pubmedid: 32905685. Pmcid: PMC8971922.
• Asamoah FA, Yarney J, Scott A, Vanderpuye V, Yuan Z, Fernandez DC, Montejo ME, Agyeman M, Boateng SN, Anarfi K, Aidoo C, Shahzad MM, Chern JY, Chon HS, Wenham RM, Yamoah K, Ahmed KA. Comparison of Definitive Cervical Cancer Management With Chemotherapy and Radiation Between Two Centers With Variable Resources and Opportunities for Improved Treatment. JCO Glob Oncol. 2020 Oct.6:1510-1518. Pubmedid: 33021855. Pmcid: PMC7605379.
• Creed JH, Berglund AE, Rounbehler RJ, Awasthi S, Cleveland JL, Park JY, Yamoah K, Gerke TA. Commercial Gene Expression Tests for Prostate Cancer Prognosis Provide Paradoxical Estimates of Race-Specific Risk. Cancer Epidemiol Biomarkers Prev. 2020 Jan.29(1):246-253. Pubmedid: 31757784. Pmcid: PMC7942810.
• Tosoian JJ, Birer SR, Jeffrey Karnes R, Zhang J, Davicioni E, Klein EE, Freedland SJ, Weinmann S, Trock BJ, Dess RT, Zhao SG, Jackson WC, Yamoah K, Pra AD, Mahal BA, Morgan TM, Mehra R, Kaffenberger S, Salami SS, Kane C, Pollack A, Den RB, Berlin A, Schaeffer EM, Nguyen PL, Feng FY, Spratt DE. Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier. Prostate Cancer P D. 2020 Dec.23(4):646-653. Pubmedid: 32231245.
• Parikh N, Keshishian E, Sharma A, Roca M, Manley B, Poch M, Grass GD, Torres-Roca J, Boulware D, Johnstone P, Montejo M, Smith J, Pow-Sang J, Yamoah K. Prostatic Artery Embolization Is Safe and Effective for Medically Recalcitrant Radiation-Induced Prostatitis. Adv Radiat Oncol. 2020 Apr.5(5):905-909. Pubmedid: 33083652. Pmcid: PMC7557125.
• Parikh N, Keshishian E, Sharma A, Roca M, Manley B, Poch M, Grass GD, Torres-Roca J, Boulware D, Johnstone P, Montejo M, Smith J, Pow-Sang J, Yamoah K. Prostatic Artery Embolization Is Safe and Effective for Medically Recalcitrant Radiation-Induced Prostatitis. Adv Radiat Oncol. 2020 Apr.
• Bhargava HK, Leo P, Elliott R, Janowczyk A, Whitney J, Gupta S, Fu P, Yamoah K, Khani F, Robinson BD, Rebbeck TR, Feldman M, Lal P, Madabhushi A. Computationally Derived Image Signature of Stromal Morphology Is Prognostic of Prostate Cancer Recurrence Following Prostatectomy in African American Patients. Clin Cancer Res. 2020 Apr.26(8):1915-1923. Pubmedid: 32139401. Pmcid: PMC7165025.
• Berglund AE, Rounbehler RJ, Gerke T, Awasthi S, Cheng CH, Takhar M, Davicioni E, Alshalalfa M, Erho N, Klein EA, Freedland SJ, Ross AE, Schaeffer EM, Trock BJ, Den RB, Cleveland JL, Park JY, Dhillon J, Yamoah K. Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer. Prostate Cancer P D. 2019 May.22(2):292-302. Pubmedid: 30367117. Pmcid: PMC6760558.
• Awasthi S, Gerke T, Park JY, Asamoah FA, Williams VL, Fink AK, Balkrishnan R, Lee DI, Malkowicz SB, Lal P, Dhillon J, Pow-Sang JM, Rebbeck TR, Yamoah K. Optimizing Time to Treatment to Achieve Durable Biochemical Disease Control after Surgery in Prostate Cancer: A Multi-Institutional Cohort Study. Cancer Epidemiol Biomarkers Prev. 2019 Mar.28(3):570-577. Pubmedid: 30413401. Pmcid: PMC8100999.
• Parra NA, Lu H, Li Q, Stoyanova R, Pollack A, Punnen S, Choi J, Abdalah M, Lopez C, Gage K, Park JY, Kosj Y, Pow-Sang JM, Gillies RJ, Balagurunathan Y. Erratum: Predicting clinically significant prostate cancer using DCE-MRI habitat descriptors. Oncotarget. 2019 Mar.10(21):2113. Pubmedid: 31007853. Pmcid: PMC6459347.
• Awasthi S, Gerke T, Williams VL, Asamoah F, Fink AK, Balkrishnan R, Park JY, Yamoah K. Interrelationship Between Health Insurance Status and Prostate Cancer Grade Can Have Critical Impact on Prostate Cancer Disease Control: A Retrospective Cohort Study. Cancer Control. 2019 Jan.26(1). Pubmedid: 30935222. Pmcid: PMC6446254.
• Asamoah FA, Yarney J, Awasthi S, Vanderpuye V, Dadzie MA, Fink A, Naghavi AO, Abrahams A, Mensah JE, Sasu E, Tagoe SN, Dhillon J, Johnstone PAS, Yamoah K. Definitive Radiation Treatment Patterns and Outcomes for Low and Intermediate Risk Prostate Cancer Patients: A Cross-Continental Comparative Study. Am J Clin Oncol. 2019 Dec.42(12):937-944. Pubmedid: 31584456. Pmcid: PMC6887629.
• Gerke T, Awasthi S, Yamoah K. Biology vs Access to Care-Relative Contribution to Racial Disparities in Prostate Cancer. JAMA Oncol. 2019 Dec.5(12):1809-1810. Pubmedid: 31670755.
• Gilligan T, Lin DW, Aggarwal R, Chism D, Cost N, Derweesh IH, Emamekhoo H, Feldman DR, Geynisman DM, Hancock SL, LaGrange C, Levine EG, Longo T, Lowrance W, McGregor B, Monk P, Picus J, Pierorazio P, Rais-Bahrami S, Saylor P, Sircar K, Smith DC, Tzou K, Vaena D, Vaughn D, Yamoah K, Yamzon J, Johnson-Chilla A, Keller J, Pluchino LA. Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2019 Dec.17(12):1529-1554. Pubmedid: 31805523.
• Echevarria MI, Awasthi S, Cheng CH, Berglund AE, Rounbehler RJ, Gerke TA, Takhar M, Davicioni E, Klein EA, Freedland SJ, Ross AE, Schaeffer EM, Den RB, Cleveland JL, Park JY, Rayford W, Yamoah K. African American Specific Gene Panel Predictive of Poor Prostate Cancer Outcome. J Urol. 2019 Aug.202(2):247-255. Pubmedid: 31107158. Pmcid: PMC7882398.
• Oliver DE, Mohammadi H, Figura N, Frakes JM, Yamoah K, Perez BA, Wuthrick EJ, Naghavi AO, Caudell JJ, Harrison LB, Torres-Roca JF, Ahmed KA. Novel Genomic-Based Strategies to Personalize Lymph Node Radiation Therapy. Semin Radiat Oncol. 2019 Apr.29(2):111-125. Pubmedid: 30827449.
• Roach M, Moughan J, Lawton CAF, Dicker AP, Zeitzer KL, Gore EM, Kwok Y, Seider MJ, Hsu IC, Hartford AC, Horwitz EM, Yamoah K, Jones CU, Michalski JM, Lee WR, Pisansky TM, Rabinovitch R, Rotman M, Pryzant RM, Kim HE, Thomas CR, Shipley WU, Sandler HM. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. Lancet Oncol. 2018 Nov.19(11):1504-1515. Pubmedid: 30316827. Pmcid: PMC6540797.
• Rounbehler RJ, Berglund AE, Gerke T, Takhar MM, Awasthi S, Li W, Davicioni E, Erho NG, Ross AE, Schaeffer EM, Klein EA, Karnes RJ, Jenkins RB, Cleveland JL, Park JY, Yamoah K. Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2018 Nov.27(11):1376-1383. Pubmedid: 30108099. Pmcid: PMC6214732.
• Williams VL, Awasthi S, Fink AK, Pow-Sang JM, Park JY, Gerke T, Yamoah K. African-American men and prostate cancer-specific mortality: a competing risk analysis of a large institutional cohort, 1989-2015. Cancer Med. 2018 May.7(5):2160-2171. Pubmedid: 29601662. Pmcid: PMC5943433.
• Asamoah FA, Yarney J, Awasthi S, Vanderpuye V, Venkat PS, Fink AK, Naghavi AO, Abrahams A, Mensah JE, Sasu E, Tagoe SNA, Johnstone PAS, Yamoah K. Contemporary Radiation Treatment of Prostate Cancer in Africa: A Ghanaian Experience. J Glob Oncol. 2018 Jul.4:1-13. Pubmedid: 30085846. Pmcid: PMC6223508.
• Parra AN, Lu H, Li Q, Stoyanova R, Pollack A, Punnen S, Choi J, Abdalah M, Lopez C, Gage K, Park JY, Kosj Y, Pow-Sang JM, Gillies RJ, Balagurunathan Y. Predicting clinically significant prostate cancer using DCE-MRI habitat descriptors. Oncotarget. 2018 Dec.9(98):37125-37136. Pubmedid: 30647849. Pmcid: PMC6324677.
• Echevarria MI, Naghavi AO, Abuodeh YA, Ahmed KA, Chevere C, Fernandez D, Yamoah K. Low-dose-rate Brachytherapy for Prostate Cancer in Low-resource Settings. Int J Radiat Oncol Biol Phys. 2017 Oct.99(2):378-382. Pubmedid: 28871987.
• Luu HN, Lin HY, Sørensen KD, Ogunwobi OO, Kumar N, Chornokur G, Phelan C, Jones D, Kidd L, Batra J, Yamoah K, Berglund A, Rounbehler RJ, Yang M, Lee SH, Kang N, Kim SJ, Park JY, Di Pietro G. miRNAs associated with prostate cancer risk and progression. BMC Urol. 2017 Mar.17(1):18. Pubmedid: 28320379. Pmcid: PMC5359825.
• Kim H, Kalchman I, Santiago-Jiménez M, Lehrer J, Guo J, Hermann G, Yamoah K, Alshalalfa M, Huang HC, Ross AE, Schaeffer EM, Davicioni E, Erho N, Yousefi K, Den RB. Transcriptome evaluation of the relation between body mass index and prostate cancer outcomes. Cancer. 2017 Jun.123(12):2240-2247. Pubmedid: 28140459.
• Jeffers A, Sochat V, Kattan MW, Yu C, Melcon E, Yamoah K, Rebbeck TR, Whittemore AS. Predicting Prostate Cancer Recurrence After Radical Prostatectomy. Prostate. 2017 Feb.77(3):291-298. Pubmedid: 27775165. Pmcid: PMC5877452.
• Yamoah K, Johnstone PA. Proton beam therapy: clinical utility and current status in prostate cancer. Onco Targets Ther. 2016 Sep.9:5721-5727. Pubmedid: 27695349. Pmcid: PMC5033502.
• Echevarria MI, Naghavi AO, Venkat PS, Abuodeh YA, Chevere C, Yamoah K. The impact of body mass index on dosimetric quality in low-dose-rate prostate brachytherapy. J Contemp Brachytherapy. 2016 Oct.8(5):386-390. Pubmedid: 27895679. Pmcid: PMC5116453.
• Naghavi AO, Echevarria M, Strom T, Abuodeh YA, Ahmed KA, Venkat PS, Trotti A, Harrison LB, Green BL, Yamoah K, Caudell JJ. Race Is Associated With Poor Outcomes in Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2016 Oct.96(2S):E407. Pubmedid: 27674609.
• Naghavi AO, Echevarria MI, Grass GD, Strom TJ, Abuodeh YA, Ahmed KA, Kim Y, Trotti AM, Harrison LB, Yamoah K, Caudell JJ. Having Medicaid insurance negatively impacts outcomes in patients with head and neck malignancies. Cancer. 2016 Nov.122(22):3529-3537. Pubmedid: 27479362. Pmcid: PMC7810134.
• Yamoah K, Zeigler-Johnson CM, Jeffers A, Malkowicz B, Spangler E, Park JY, Whittemore A, Rebbeck TR. The impact of body mass index on treatment outcomes for patients with low-intermediate risk prostate cancer. BMC Cancer. 2016 Jul.16:557. Pubmedid: 27473687. Pmcid: PMC4966583.
• Naghavi AO, Echevarria MI, Strom TJ, Abuodeh YA, Ahmed KA, Venkat PS, Trotti A, Harrison LB, Green BL, Yamoah K, Caudell JJ. Treatment delays, race, and outcomes in head and neck cancer. Cancer Epidemiol. 2016 Dec.45:18-25. Pubmedid: 27664388.
• Yamoah K, Johnson MH, Choeurng V, Faisal FA, Yousefi K, Haddad Z, Ross AE, Alshalafa M, Den R, Lal P, Feldman M, Dicker AP, Klein EA, Davicioni E, Rebbeck TR, Schaeffer EM. Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer. J Clin Oncol. 2015 Sep.33(25):2789-2796. Pubmedid: 26195723. Pmcid: PMC4550692.
• Palmer JD, Siglin J, Yamoah K, Dan T, Champ CE, Bar-Ad V, Werner-Wasik M, Evans JJ, Kim L, Glass J, Farrell C, Andrews DW, Shi W. Re-resection for recurrent high-grade glioma in the setting of re-irradiation: more is not always better. J Neurooncol. 2015 Sep.124(2):215-221. Pubmedid: 26024653.
• Yamoah K, Showalter TN, Ohri N. Radiation Therapy Intensification for Solid Tumors: A Systematic Review of Randomized Trials. Int J Radiat Oncol Biol Phys. 2015 Nov.93(4):737-745. Pubmedid: 26530740. Pmcid: PMC4635974.
• Eldredge-Hindy HB, Duffy D, Yamoah K, Simone NL, Skowronski J, Dicker AP, Anne PR. Modeled risk of ischemic heart disease following left breast irradiation with deep inspiration breath hold. Pract Radiat Oncol. 2015 May.5(3):162-168. Pubmedid: 25957186.
• Grover S, Balogun OD, Yamoah K, Groen R, Shah M, Rodin D, Martei Y, Olson AC, Slone JS, Shulman LN, Coleman CN, Hahn SM. Corrigendum: "Training Global Oncologists: Addressing the Global Cancer Control Problem". Front Oncol. 2015 Jun.5:133. Pubmedid: 26114095. Pmcid: PMC4461853.
• Yamoah K, Deville C, Vapiwala N, Spangler E, Zeigler-Johnson CM, Malkowicz B, Lee DI, Kattan M, Dicker AP, Rebbeck TR. African American men with low-grade prostate cancer have increased disease recurrence after prostatectomy compared with Caucasian men. Urol Oncol. 2015 Feb.33(2):70.e15-70.e22. Pubmedid: 25304288. Pmcid: PMC4980822.
• Grover S, Balogun OD, Yamoah K, Groen R, Shah M, Rodin D, Olson AC, Slone JS, Shulman LN, Coleman CN, Hahn SM. Training global oncologists: addressing the global cancer control problem. Front Oncol. 2015 Apr.5:80. Pubmedid: 25905040. Pmcid: PMC4389376.
• Yamoah K, Walker A, Spangler E, Zeigler-Johnson CM, Malkowicz B, Lee DI, Dicker AP, Rebbeck TR, Lal P. African-american race is a predictor of seminal vesicle invasion after radical prostatectomy. Clin Genitourin Cancer. 2015 Apr.13(2):e65-e72. Pubmedid: 25450037. Pmcid: PMC4980819.
• Yamoah K, Eldredge-Hindy HB, Zaorsky NG, Palmer JD, Doyle LA, Sendecki JA, Hesney AA, Harper L, Repka M, Showalter TN, Hurwitz MD, Dicker AP, Den RB. Large prostate gland size is not a contraindication to low-dose-rate brachytherapy for prostate adenocarcinoma. Brachytherapy. 2014 Oct.13(5):456-464. Pubmedid: 24953945.
• Zaorsky NG, Yamoah K, Thakur ML, Trabulsi EJ, Showalter TN, Hurwitz MD, Dicker AP, Den RB. A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer. Future Oncol. 2014 Feb.10(3):457-474. Pubmedid: 24559451. Pmcid: PMC6615465.
• Yamoah K, Zaorsky NG, Siglin J, Shi W, Werner-Wasik M, Andrews DW, Dicker AP, Bar-Ad V, Liu H. Spine Stereotactic Body Radiation Therapy Residual Setup Errors and Intra-Fraction Motion Using the Stereotactic X-Ray Image Guidance Verification System. Int J Med Phys Clin Eng Radiat Oncol. 2014 Feb.3(1):1-8. Pubmedid: 29333353. Pmcid: PMC5766040.
• Zaorsky NG, Doyle LA, Yamoah K, Andrel JA, Trabulsi EJ, Hurwitz MD, Dicker AP, Den RB. High dose rate brachytherapy boost for prostate cancer: a systematic review. Cancer Treat Rev. 2014 Apr.40(3):414-425. Pubmedid: 24231548.
• Yamoah K, Beecham K, Hegarty SE, Hyslop T, Showalter T, Yarney J. Early results of prostate cancer radiation therapy: an analysis with emphasis on research strategies to improve treatment delivery and outcomes. BMC Cancer. 2013 Jan.13:23. Pubmedid: 23324165. Pmcid: PMC3558339.
• Yamoah K, Stone N, Stock R. Impact of race on biochemical disease recurrence after prostate brachytherapy. Cancer. 2011 Dec.117(24):5589-5600. Pubmedid: 21692058.
• Fang L, Wang X, Yamoah K, Chen PL, Pan ZQ, Huang L. Characterization of the human COP9 signalosome complex using affinity purification and mass spectrometry. J Proteome Res. 2008 Nov.7(11):4914-4925. Pubmedid: 18850735. Pmcid: PMC2676908.
• Yamoah K, Brebene A, Baliram R, Inagaki K, Dolios G, Arabi A, Majeed R, Amano H, Wang R, Yanagisawa R, Abe E. High-mobility group box proteins modulate tumor necrosis factor-alpha expression in osteoclastogenesis via a novel deoxyribonucleic acid sequence. Mol Endocrinol. 2008 May.22(5):1141-1153. Pubmedid: 18218727. Pmcid: PMC2366181.
• Sun L, Vukicevic S, Baliram R, Yang G, Sendak R, McPherson J, Zhu LL, Iqbal J, Latif R, Natrajan A, Arabi A, Yamoah K, Moonga BS, Gabet Y, Davies TF, Bab I, Abe E, Sampath K, Zaidi M. Intermittent recombinant TSH injections prevent ovariectomy-induced bone loss. Proc Natl Acad Sci U S A. 2008 Mar.105(11):4289-4294. Pubmedid: 18332426. Pmcid: PMC2393772.
• Yamoah K, Oashi T, Sarikas A, Gazdoiu S, Osman R, Pan ZQ. Autoinhibitory regulation of SCF-mediated ubiquitination by human cullin 1's C-terminal tail. Proc Natl Acad Sci U S A. 2008 Aug.105(34):12230-12235. Pubmedid: 18723677. Pmcid: PMC2519045.
• Kumar A, Wu H, Collier-Hyams LS, Hansen JM, Li T, Yamoah K, Pan ZQ, Jones DP, Neish AS. Commensal bacteria modulate cullin-dependent signaling via generation of reactive oxygen species. Embo J. 2007 Oct.26(21):4457-4466. Pubmedid: 17914462. Pmcid: PMC2063476.
• Gazdoiu S, Yamoah K, Wu K, Pan ZQ. Human Cdc34 employs distinct sites to coordinate attachment of ubiquitin to a substrate and assembly of polyubiquitin chains. Mol Cell Biol. 2007 Oct.27(20):7041-7052. Pubmedid: 17698585. Pmcid: PMC2168909.
• Abe E, Sun L, Mechanick J, Iqbal J, Yamoah K, Baliram R, Arabi A, Moonga BS, Davies TF, Zaidi M. Bone loss in thyroid disease: role of low TSH and high thyroid hormone. Ann Ny Acad Sci. 2007 Nov.1116:383-391. Pubmedid: 18083940.
• Sun L, Peng Y, Zaidi N, Zhu LL, Iqbal J, Yamoah K, Wang X, Liu P, Abe E, Moonga BS, Epstein S, Zaidi M. Evidence that calcineurin is required for the genesis of bone-resorbing osteoclasts. Am J Physiol Renal Physiol. 2007 Jan.292(1):F285-F291. Pubmedid: 16968888.
• Gazdoiu S, Yamoah K, Wu K, Escalante CR, Tappin I, Bermudez V, Aggarwal AK, Hurwitz J, Pan ZQ. Proximity-induced activation of human Cdc34 through heterologous dimerization. Proc Natl Acad Sci U S A. 2005 Oct.102(42):15053-15058. Pubmedid: 16210246. Pmcid: PMC1242854.
• Yamoah K, Wu K, Pan ZQ. In vitro cleavage of Nedd8 from cullin 1 by COP9 signalosome and deneddylase 1. Methods Enzymol. 2005.398:509-522. Pubmedid: 16275355.
• Pan ZQ, Kentsis A, Dias DC, Yamoah K, Wu K. Nedd8 on cullin: building an expressway to protein destruction. Oncogene. 2004 Mar.23(11):1985-1997. Pubmedid: 15021886.
• Wu K, Yamoah K, Dolios G, Gan-Erdene T, Tan P, Chen A, Lee CG, Wei N, Wilkinson KD, Wang R, Pan ZQ. DEN1 is a dual function protease capable of processing the C terminus of Nedd8 and deconjugating hyper-neddylated CUL1. J Biol Chem. 2003 Aug.278(31):28882-28891. Pubmedid: 12759363.

• Title: To develop and evaluate an AI-based prognostic and predictive models that may inform decisions for localized prostate cancer in patients undergoing prostatectomy and radiation therapy
  Sponsor: Artera, Inc.
  PI: Grass, G., CO-PI: Yamoah, K.
• Title: Targeting tumor cell macrophage lipid interactions to overcome resistance to androgen receptor targeted therapy.
  Sponsor: Nat Institutes of Health
  PI: Yamoah, K.
• Title: Deconvolute Key Biological Drivers That Define Subsets of Lethal Prostate Cancer in African American Men
  Sponsor: US Army
  PI: Yamoah, K.
• Title: Disrupting the Prostate Tumor Microenvironment in African American Men to Promote Response to Immune-modulatory Therapy
  Sponsor: Nat Institutes of Health
  PI: Yamoah, K.
• Title: The Rate Elements Skewing Outcomes Linked to Veteran Equity in PCa (RESOLVE PCa) Consortium: Mulitilevel modeling to Predict Prostate Cancer Incidence and Aggressiveness
  Sponsor: Prostate Cancer Fdtn
  PI: Yamoah, K.
• Title: Genomic Diversity of Prostate Cancer Across the African Diaspora
  Sponsor: Nat Institutes of Health
  PI: Yamoah, K.
• Title: The John and Daria Barry Foundation Precision Oncology Center of Excellence in the VA Sunshine Healthcare Network
  Sponsor: Prostate Cancer Fdtn
  PI: Yamoah, K.
• Title: Identification & Validation of a Biomarker Signature That Can Improve Predictability of Aggressive Disease in Men of African Descent with Prostate Cancer
  Sponsor: Prostate Cancer Fdtn
  PI: Yamoah, K.
• Title: Ghana IntegRative Approach to Cancer ResEarch Training: The Grace Program
  Sponsor: Nat Institutes of Health
  PI (Contact): Yamoah, K., PI (MPI): Giuliano, A.